Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astri Therapeutics Inc (NQ: ATXS )

9.150 +0.040 (+0.44%)
Streaming Delayed Price Updated: 12:57 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 74,741
Open 9.150
Bid (Size) 9.120 (4)
Ask (Size) 9.180 (5)
Prev. Close 9.110
Today's Range 9.000 - 9.350
52wk Range 4.260 - 16.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
From Astria Therapeutics, Inc.
Via Business Wire
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024
ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+17.46%
+17.46%
1 Month
-6.63%
-6.63%
3 Month
-29.51%
-29.51%
6 Month
+106.08%
+106.08%
1 Year
-30.42%
-30.42%

More News

Read More
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Earnings Preview For Astria Therapeutics
Via Benzinga
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
From Astria Therapeutics, Inc.
Via Business Wire
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
From Astria Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
$5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For November 13, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.